In a report released today, Debjit Chattopadhyay from H.C. Wainwright initiated coverage with a Buy rating on Voyager Therapeutics Inc (NASDAQ: VYGR) and a price target of $30. The company’s shares closed on Friday at $20.41.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 4.0% and a 50.8% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Voyager Therapeutics Inc is Strong Buy and the average price target is $34.71, representing a 70.1% upside.
In a report issued on May 20, Cowen & Co. also assigned a Buy rating to the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31.91 and a one-year low of $8.10. Currently, Voyager Therapeutics Inc has an average volume of 439.4K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops life-changing treatments for patients suffering from central nervous system. It focuses in the field of adeno-associated virus gene therapy through innovation and investment in vector optimization and engineering, and dosing techniques, as well as process development and production. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
